Viewing Study NCT02614833

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2026-02-27 @ 6:54 AM
Study NCT ID: NCT02614833
Status: COMPLETED
Last Update Posted: 2021-10-05
First Post: 2015-11-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Sponsor: Immutep S.A.S.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Adenocarcinoma Breast Stage IV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hormone receptor positive View